Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM26R4P)

Drug Name
N-benzylacetimidamide hydrobromide Drug Info
Synonyms
N-Benzylacetamidine Hydrobromide; 186545-76-6; CHEMBL462334; 1-(Benzylamino)ethaniminium bromide; N-benzylacetimidamide hydrobromide; C9H12N2.HBr; CTK8E6104; DTXSID10649404; MolPort-009-019-600; 1916AH; AKOS025294782; RT-023317; J-011977; (1E)-N'-Benzylethanimidamide--hydrogen bromide (1/1)
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
25231659
CAS Number
CAS 186545-76-6
TTD Drug ID
DM26R4P

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Nitric-oxide synthase inducible (NOS2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Curcumin DMQPH29 Solid tumour/cancer 2A00-2F9Z Phase 3 [2]
SD-6010 DM9DEYL Osteoarthritis FA00-FA05 Phase 3 [3]
MPL-S DMNDCFY Endotoxic shock 1G41 Phase 3 [4]
Pimagedine HCl DMPWH30 Diabetic kidney disease GB61.Z Phase 2/3 [5]
GW274150 DMZMCB1 Asthma CA23 Phase 2 [6]
BXT-51072 DMD8GNB Cardiovascular disease BA00-BE2Z Phase 2 [7]
HP-228 DMNZ35F Postoperative pain MG30-MG3Z Phase 2 [8]
CR-3294 DMHJEZS Diarrhea ME05.1 Phase 2 [9]
KD-7040 DME1WV2 Pain MG30-MG3Z Phase 2 [10]
LT-1951 DM5N04G Coronary artery disease BA80 Phase 1/2 [11]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Nitric-oxide synthase inducible (NOS2) TTF10I9 NOS2_HUMAN Inhibitor [1]

References

1 N-Substituted acetamidines and 2-methylimidazole derivatives as selective inhibitors of neuronal nitric oxide synthase. Bioorg Med Chem Lett. 2010 Nov 15;20(22):6495-9.
2 A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20523-8.
3 A 2-year randomised, double-blind, placebo-controlled, multicentre study of oral selective iNOS inhibitor, cindunistat (SD-6010), in patients with symptomatic osteoarthritis of the knee. Ann Rheum Dis. 2013 Feb;72(2):187-95.
4 Lipopolysaccharide and monophosphoryl lipid A differentially regulate interleukin-12, gamma interferon, and interleukin-10 mRNA production in murine macrophages. Infect Immun. 1997 Aug;65(8):3239-47.
5 Nitric oxide associated with iNOS expression inhibits acetylcholinesterase activity and induces memory impairment during acute hypobaric hypoxia. Brain Res. 2008 Sep 16;1230:138-49.
6 GW274150, a potent and highly selective inhibitor of iNOS, reduces experimental renal ischemia/reperfusion injury. Kidney Int. 2003 Mar;63(3):853-65.
7 Shear stress induces iNOS expression in cultured smooth muscle cells: role of oxidative stress. Am J Physiol Cell Physiol. 2000 Dec;279(6):C1880-8.
8 HP-228, a novel synthetic peptide, inhibits the induction of nitric oxide synthase in vivo but not in vitro. J Pharmacol Exp Ther. 1995 Nov;275(2):584-91.
9 Efficacy of CR3294, a new benzamidine derivative, in the prevention of 5-fluorouracil-induced gastrointestinal mucositis and diarrhea in mice. Cancer Chemother Pharmacol. 2010 October; 66(5): 819-827.
10 WO patent application no. 2014,0214,08, Method for treating cancer by anticancer agent co-administration.
11 Critical role of L-arginine in endothelial cell survival during oxidative stress. Circulation. 2003 May 27;107(20):2607-14.